|Bid||0.7900 x 3000|
|Ask||0.8599 x 1100|
|Day's Range||0.8200 - 0.9000|
|52 Week Range||0.7800 - 2.9600|
|Beta (3Y Monthly)||1.18|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 18, 2017 - Oct 23, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
In 1997 Shai Gozani was appointed CEO of NeuroMetrix, Inc. (NASDAQ:NURO). First, this article will compare CEO compensation with compensation at similar sized companies. Then we'll look at a snap Read More...
NEW YORK, NY / ACCESSWIRE / December 12, 2018 / NeuroMetrix and Moleculin were both up almost 19% in Tuesday’s trading session. Traders were gearing up for Moleculin’s conference call today discussing a recent discovery of a use of one of its molecules for cancer treatment while NeuroMetrix announced an update on its strategic collaboration with GSK Consumer Healthcare. NeuroMetrix, Inc. shares were up nearly 19% on almost 1.7 million shares traded on Tuesday.
Under terms of the collaboration entered into in the first quarter of 2018, the parties committed to co-fund future development of Quell® technology beginning in 2019, subject to agreement on an annual program of product initiatives. The Company reported that agreement has been reached on the 2019 development program and it will commence in January 2019.
WALTHAM, Mass., Nov. 28, 2018 -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Shai N. Gozani M.D., Ph.D., President and CEO of NeuroMetrix, is scheduled to speak at the.
NeuroMetrix, Inc. (NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,130,810 titled “Transcutaneous electrical nerve stimulation with user gesture detector and electrode-skin contact detector, with transient motion detector for increasing the accuracy of the same.” This patent covers our novel technology that enhances Quell® device performance for users with an active lifestyle. Quell is an advanced, wearable technology for treating chronic pain. Quell is drug-free and has been cleared by the FDA for treatment of chronic pain without a prescription.
WALTHAM, Mass., Nov. 15, 2018 -- NeuroMetrix, Inc. (Nasdaq:NURO), announced today that it had executed a distribution agreement with Fukuda Denshi Co. Ltd. for DPNCheck®, the.
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Quell is an advanced, wearable technology for treating chronic pain. Quell is drug-free and has been cleared by the FDA for treatment of chronic pain without a prescription. Quell has been shown in multiple clinical studies to relieve chronic pain and, in a published study, 4 out of 5 users reported improvement in chronic pain. Quell users can personalize and manage therapy discreetly via the Quell app. Quell also offers health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait.
NEW YORK, NY / ACCESSWIRE / October 17, 2018 / NeuroMetrix, Inc. (NASDAQ: NURO ) will be discussing their earnings results in their 2018 Third Quarter Earnings to be held on October 17, 2018 at 8:00 AM ...
NeuroMetrix, Inc. (NURO) announced today that it plans to issue its 2018 third quarter financial results before the opening of the market on Wednesday, October 17, 2018. The Company will host a conference call at 8:00 a.m., Eastern Time on October 17, 2018 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 2189578.
Every investor in NeuroMetrix Inc (NASDAQ:NURO) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders owning Read More...
NeuroMetrix, Inc. (NURO), today reported publication of a clinical study of Quell® wearable pain relief in the Journal of Pain and Relief. The paper is titled “Real-World Evidence for the Widespread Effects of Fixed-Site High Frequency Transcutaneous Electrical Nerve Stimulation in Chronic Pain.” It is available for download at: Journal of Pain and Relief. Quell was used an average of 36 hours per week by the study participants for 60 days. Study participants reported statistically and clinically significant decreases in pain interference with activity and mood. Daily users also reported a clinically significant decrease in pain intensity and less pain interference with sleep.
NeuroMetrix, Inc. (NURO), today announced that it will showcase its latest product innovation, Quell® 2.0 Wearable Pain Relief Technology™, during a workshop at DTxDM East, and will discuss using real world, patient generated data to improve outcomes for people living with chronic pain. "We are excited to share how user feedback has helped shape innovation in our Quell technology, and how data collected from the Quell Health Cloud is fueling scientific research into chronic pain," said Frank McGillin, Senior Vice President and CCO of NeuroMetrix. Quell is an advanced, wearable technology for treating chronic pain.
WALTHAM, Mass., Sept. 20, 2018-- NeuroMetrix, Inc., reported that its President and CEO, Dr. Shai N. Gozani, yesterday participated in a discussion of the opioid crisis and the Company’ s Quell ® Wearable ...
LAS VEGAS, Sept. 4, 2018 /PRNewswire/ -- Tomorrow at PAINWeek 2018, NeuroMetrix Inc. (NURO), will unveil its latest breakthrough for the treatment of chronic pain. With economic costs estimated to be $635 billion per year, chronic pain is one of the most complex conditions for care providers and patients to manage, making it ripe for innovation. An estimated 100 million Americans are living with some form of chronic pain, and with the rise of the opioid epidemic, are increasingly searching for new, drug-free treatment methods.
LONDON, UK / ACCESSWIRE / July 25, 2018 / If you want access to our free earnings report on Intuitive Surgical, Inc. (NASDAQ: ISRG), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ISRG. The Company reported its second quarter fiscal 2018 operating and financial results on July 19, 2018. Additionally, the Company provided its guidance for FY18.